DK1465617T3 - Fremgangsmåde til at påvirke neurologisk progression - Google Patents
Fremgangsmåde til at påvirke neurologisk progressionInfo
- Publication number
- DK1465617T3 DK1465617T3 DK02799240T DK02799240T DK1465617T3 DK 1465617 T3 DK1465617 T3 DK 1465617T3 DK 02799240 T DK02799240 T DK 02799240T DK 02799240 T DK02799240 T DK 02799240T DK 1465617 T3 DK1465617 T3 DK 1465617T3
- Authority
- DK
- Denmark
- Prior art keywords
- influencing
- procedures
- neurological progression
- neurological
- progression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
- A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33965001P | 2001-12-13 | 2001-12-13 | |
| US34658402P | 2002-01-07 | 2002-01-07 | |
| US35309002P | 2002-01-30 | 2002-01-30 | |
| PCT/US2002/039974 WO2003049731A1 (en) | 2001-12-13 | 2002-12-12 | Process for affecting neurologic progression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1465617T3 true DK1465617T3 (da) | 2009-02-16 |
Family
ID=27407352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02799240T DK1465617T3 (da) | 2001-12-13 | 2002-12-12 | Fremgangsmåde til at påvirke neurologisk progression |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20030130252A1 (es) |
| EP (1) | EP1465617B1 (es) |
| JP (1) | JP2005511719A (es) |
| KR (1) | KR20040075001A (es) |
| CN (1) | CN1615129A (es) |
| AT (1) | ATE411017T1 (es) |
| AU (1) | AU2002364165B2 (es) |
| CA (1) | CA2469613A1 (es) |
| DE (1) | DE60229437D1 (es) |
| DK (1) | DK1465617T3 (es) |
| ES (1) | ES2315429T3 (es) |
| IL (1) | IL162469A0 (es) |
| MX (1) | MXPA04005715A (es) |
| PL (1) | PL372326A1 (es) |
| PT (1) | PT1465617E (es) |
| WO (1) | WO2003049731A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2595236A1 (en) * | 2005-01-19 | 2006-07-27 | Pharmacyclics, Inc. | A method for treating neurologic diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252720A (en) * | 1989-03-06 | 1993-10-12 | Board Of Regents, The University Of Texas System | Metal complexes of water soluble texaphyrins |
| US5457183A (en) * | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5776925A (en) * | 1996-01-25 | 1998-07-07 | Pharmacyclics, Inc. | Methods for cancer chemosensitization |
| US6013646A (en) * | 1998-07-02 | 2000-01-11 | Bayer Corporation | Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer |
-
2002
- 2002-12-12 US US10/318,659 patent/US20030130252A1/en not_active Abandoned
- 2002-12-12 PT PT02799240T patent/PT1465617E/pt unknown
- 2002-12-12 ES ES02799240T patent/ES2315429T3/es not_active Expired - Lifetime
- 2002-12-12 EP EP02799240A patent/EP1465617B1/en not_active Expired - Lifetime
- 2002-12-12 CA CA002469613A patent/CA2469613A1/en not_active Abandoned
- 2002-12-12 DK DK02799240T patent/DK1465617T3/da active
- 2002-12-12 CN CNA028270924A patent/CN1615129A/zh active Pending
- 2002-12-12 JP JP2003550780A patent/JP2005511719A/ja active Pending
- 2002-12-12 AU AU2002364165A patent/AU2002364165B2/en not_active Ceased
- 2002-12-12 WO PCT/US2002/039974 patent/WO2003049731A1/en active Application Filing
- 2002-12-12 DE DE60229437T patent/DE60229437D1/de not_active Expired - Fee Related
- 2002-12-12 IL IL16246902A patent/IL162469A0/xx unknown
- 2002-12-12 PL PL02372326A patent/PL372326A1/xx not_active Application Discontinuation
- 2002-12-12 KR KR10-2004-7009132A patent/KR20040075001A/ko not_active Application Discontinuation
- 2002-12-12 AT AT02799240T patent/ATE411017T1/de not_active IP Right Cessation
- 2002-12-12 MX MXPA04005715A patent/MXPA04005715A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PT1465617E (pt) | 2009-01-23 |
| EP1465617A1 (en) | 2004-10-13 |
| WO2003049731A1 (en) | 2003-06-19 |
| EP1465617A4 (en) | 2005-10-12 |
| ES2315429T3 (es) | 2009-04-01 |
| MXPA04005715A (es) | 2004-10-15 |
| CN1615129A (zh) | 2005-05-11 |
| CA2469613A1 (en) | 2003-06-19 |
| AU2002364165B2 (en) | 2007-09-20 |
| AU2002364165A1 (en) | 2003-06-23 |
| IL162469A0 (en) | 2005-11-20 |
| US20030130252A1 (en) | 2003-07-10 |
| DE60229437D1 (de) | 2008-11-27 |
| ATE411017T1 (de) | 2008-10-15 |
| PL372326A1 (en) | 2005-07-11 |
| JP2005511719A (ja) | 2005-04-28 |
| EP1465617B1 (en) | 2008-10-15 |
| KR20040075001A (ko) | 2004-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY130718A (en) | Antitumor compounds and methods | |
| ZA200305126B (en) | Methods of administering epothilone analogs for the treatment of cancer. | |
| MXPA05011643A (es) | 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension. | |
| MXPA03011197A (es) | Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales. | |
| BR0213424A (pt) | Uso aperfeiçoado de composto antitumoral na terapia contra câncer | |
| HK1068626A1 (en) | Chemical compounds | |
| MY142988A (en) | Novel aminobenzophenone compounds | |
| DK1187632T3 (da) | Behandling med anti-ErbB2-antistoffer | |
| HK1116339A1 (en) | Methods of administering epothilone analogs for the treatment of cancer | |
| UA90698C2 (en) | Triazole substituted aminobenzophenone compounds | |
| IS6964A (is) | Ónæmismeðferðarsamsetningar til meðhöndlunar á æxlum sem oftjá ganglíósíð | |
| IS7137A (is) | Samsett meðferð til meðhöndlunar á krabbameini | |
| ZA200404752B (en) | 6-aminomorphinane derivatives method for the production and use thereof | |
| BRPI0607285A2 (pt) | tratamento de tumores com metástases | |
| HUP0402341A3 (en) | Compositions containing thiazol-2-ylamines for the treatment of cancer | |
| DK1465617T3 (da) | Fremgangsmåde til at påvirke neurologisk progression | |
| SE0002739D0 (sv) | New use | |
| MXPA04003910A (es) | Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar. | |
| MXPA03006412A (es) | Metodos para administrar analogos de epotilona para tratamiento de cancer. | |
| MXPA03006866A (es) | Modificacion cristalina de depsipeptido ciclico con actividad mejorada. | |
| HN2002000335A (es) | Compuestos asapoliciclicos condensados con arilo | |
| PT1427420E (pt) | Utilizacao de uma combinacao compreendendo 4- piridilmetilftalazinas para o tratamento do cancro | |
| EP1459754A4 (en) | MEANS FOR THE PREVENTION / TREATMENT OF CANCER | |
| TW200603801A (en) | Novel dialkoxy-imidazopyridines | |
| CA97933S (en) | Hose clamp |